Evidence map›Paper›PMID 41646270›Full record

ArticleESMO gastrointestinal oncology2025

Prognostic factors for overall survival in advanced digestive neuroendocrine carcinoma treated with first-line cisplatin-based chemotherapy: a

H Hirano, K Hirata, Y Honma, C Morizane, N Machida, K Kato, T Okusaka, N Boku, S Sekine, N Hiraoka and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

H HiranoDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
K HirataKeio Cancer Center, Keio University School of Medicine, Tokyo, Japan.
Y HonmaDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
C MorizaneDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
N MachidaDepartment of Gastroenterology, Kanagawa Cancer Center Hospital, Kanagawa, Japan.
K KatoDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
T OkusakaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
N BokuDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
S SekineDivision of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
N HiraokaDivision of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
J MizusawaJCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Y SanoJCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Y ShibuyaDepartment of Gastroenterology Surgery, Kochi Health Sciences Center, Kochi, Japan.
M TakahashiDepartment of Medical Oncology, Tohoku University Hospital, Miyagi, Japan.
N FujimoriDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
M NomuraDepartment of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan.
Y DokiDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
M UenoDepartment of Gastroenterology, Kanagawa Cancer Center Hospital, Kanagawa, Japan.
T YoshikawaDepartment of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan.
H TakeuchiDepartment of Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There is no consensus on prognostic factors for advanced digestive neuroendocrine carcinoma (ADNEC). JCOG1213 was a phase III randomized trial that demonstrated equivalent overall survival (OS) between cisplatin plus etoposide and cisplatin plus irinotecan as first-line chemotherapy for ADNEC. We aimed to retrospectively explore prognostic factors for OS in patients with ADNEC using data from JCOG1213. Patients and methods: The patients included in this Results: Among 170 patients enrolled in JCOG1213, a total of 129 patients with ADNEC were included in this analysis. Multivariable analysis identified elevated serum lactate dehydrogenase (LDH; >222 IU/l) as a significantly unfavorable prognostic factor for OS [hazard ratio (HR) 1.721, 95% confidence interval (CI) 1.144-2.589, Conclusion: Serum LDH may serve as a simple, non-invasive, and clinically informative biomarker for prognostic evaluation in patients with ADNEC undergoing first-line platinum-based chemotherapy.

Indexed as

cisplatinfirst-line chemotherapygastroenteropancreatic neuroendocrine carcinomaprognostic factor

Identifiers

PMID41646270
PMCPMC12836487

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.